Lindynette (Ethinylestradiol, Gestodene)

Ethinylestradiol, combined with gestodene, binds to estrogen receptors and suppresses the release of gonadotropins from the pituitary gland. This suppression blocks ovulation, while the progestogen component thickens cervical mucus and modifies the uterine lining, making it difficult for sperm to reach an egg and for implantation to occur.

The dosing regimen for Lindynette is determined by the prescribing healthcare professional. Typically, it involves a 21‑day active tablet sequence followed by a 7‑day hormone‑free interval, but the exact schedule and any adjustments are individualized based on the patient’s medical history and clinical judgment.

Lindynette is not intended for use during pregnancy and should be discontinued if pregnancy occurs. While limited data exist for breastfeeding, combined oral contraceptives are generally considered compatible with lactation, though clinicians may evaluate individual risk‑benefit considerations, especially in the early postpartum period.

To place an order, submit an enquiry on the Lindynette product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lindynette contains ethinyloestradiol and gestodene, a low‑dose estrogen‑progestogen combination that offers a favorable bleeding profile and lower androgenic activity compared with some older formulations. Its efficacy in preventing pregnancy is comparable to other COCs, while its side‑effect profile may differ slightly based on the specific progestogen used.

Lindynette tablets should be stored at ambient temperature, below 25 °C, in the original blister pack to protect them from moisture and light. Keep the medication out of reach of children and avoid storing it in bathrooms or other humid environments.

Lindynette is taken orally, once daily, at the same time each day. The typical regimen includes 21 consecutive active tablets followed by a 7‑day hormone‑free interval, during which withdrawal bleeding occurs. Patients should follow the schedule prescribed by their healthcare provider.

Serious risks include venous thromboembolism, pulmonary embolism, stroke, myocardial infarction, and severe allergic reactions. These events are more likely in women who smoke, are over 35, have a history of clotting disorders, or possess certain cardiovascular risk factors. Prompt medical attention is required if symptoms arise.

Lindynette is contraindicated in women with a history of thromboembolic disease, uncontrolled hypertension, active liver disease, known or suspected breast cancer, or those who are pregnant. It should also be avoided by women over 35 who smoke and by individuals with known hypersensitivity to any component of the tablet.